Why the study?
Does ablation of ALCAT1 prevent T4-induced cardiomyopathy and mitochondrial dysfunction in preclinical models?
Population
H9c2 cardiac cells and T4-induced cardiomyopathy model
Comparison
Ablation of ALCAT1 (ALCAT1 deficiency) vs Wild-type/control
Design
Preclinical
Authors
Loading...
Supports ALCAT1 as a preclinical target in T4-cardiomyopathy; hypothesis-generating with no clinical implications yet.
Does ablation of ALCAT1 prevent T4-induced cardiomyopathy and mitochondrial dysfunction in preclinical models?
Ablation of ALCAT1 prevents T4-induced cardiomyopathy and mitigates mitochondrial dysfunction, highlighting its role as a link between oxidative stress and age-related heart diseases.
Liu et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: